Pharmacology and therapeutics of bronchodilators revisited
MG Matera, CP Page, L Calzetta, P Rogliani… - Pharmacological …, 2020 - ASPET
Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …
[HTML][HTML] Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies …
TH Harries, V Rowland, CJ Corrigan, IJ Marshall… - Respiratory …, 2020 - Springer
Background Blood eosinophil count has been proposed as a predictor of response to
inhaled corticosteroid (ICS) in the prevention of acute exacerbations of COPD. An optimal …
inhaled corticosteroid (ICS) in the prevention of acute exacerbations of COPD. An optimal …
Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline
JD Chalmers, IF Laska, FME Franssen… - European …, 2020 - Eur Respiratory Soc
Inhaled corticosteroids (ICS) combined with bronchodilators can reduce the frequency of
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …
[HTML][HTML] Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis
A Koarai, M Yamada, T Ichikawa, N Fujino… - Respiratory …, 2021 - Springer
Background Recently, the addition of inhaled corticosteroid (ICS) to long-acting muscarinic
antagonist (LAMA) and long-acting beta-agonist (LABA) combination therapy has been …
antagonist (LAMA) and long-acting beta-agonist (LABA) combination therapy has been …
Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo
P Rogliani, MG Matera, F Facciolo… - British Journal of …, 2020 - Wiley Online Library
Background and Purpose Combining inhaled corticosteroids (ICSs), long‐acting β2‐
adrenoceptor agonists (LABAs) and long‐acting muscarinic antagonists (LAMAs) is …
adrenoceptor agonists (LABAs) and long‐acting muscarinic antagonists (LAMAs) is …
[HTML][HTML] Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine …
P Rogliani, MG Matera, C Page, E Puxeddu… - Respiratory …, 2019 - Springer
Background To date there are no head-to-head studies comparing different
mucolytic/antioxidant agents. Considering the inconsistent evidence resulting from the …
mucolytic/antioxidant agents. Considering the inconsistent evidence resulting from the …
Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies
L Calzetta, BL Ritondo, P de Marco… - Expert Review of …, 2021 - Taylor & Francis
Objectives In some studies comparing triple with dual combination therapies in COPD there
might be a possible effect of inhaler bias resulting from different inhaler devices being used …
might be a possible effect of inhaler bias resulting from different inhaler devices being used …
[HTML][HTML] The potential role and regulatory mechanisms of MUC5AC in chronic obstructive pulmonary disease
J Li, Z Ye - Molecules, 2020 - mdpi.com
Chronic obstructive pulmonary disease (COPD) is associated with high morbidity and
mortality globally. Studies show that airway mucus hypersecretion strongly compromises …
mortality globally. Studies show that airway mucus hypersecretion strongly compromises …
[HTML][HTML] LABA/LAMA as first-line therapy for COPD: a summary of the evidence and guideline recommendations
M Miravitlles, T Kawayama, M Dreher - Journal of Clinical Medicine, 2022 - mdpi.com
Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …
symptomatic patients with COPD, either as initial/first-line treatment or for second …
Eosinophils in COPD—Current concepts and clinical implications
K Mycroft, R Krenke, K Górska - The Journal of Allergy and Clinical …, 2020 - Elsevier
In recent years, heterogeneity in chronic obstructive pulmonary disease (COPD)
inflammatory patterns has been recognized as a basis for more precise treatment …
inflammatory patterns has been recognized as a basis for more precise treatment …